This research study is examining the effect of adding a fixed duration of copanlisib to
ibrutinib in select participants who have been on ibrutinib for at least six months for
relapsed/refractory chronic lymphocytic leukemia (CLL).
The names of the study drugs involved in this study are:
- Copanlisib
- Ibrutinib